بعد خبر الدواء فايوكس . Reuters Panel OKs Merck's Vioxx Return to Market GAITHERSBURG, Md. (Reuters) - Merck & Co. Inc.'s (NYSE:MRK - News) withdrawn arthritis drug Vioxx is safe enough to rejoin Pfizer's rival pain relievers Celebrex and Bextra on the U.S. market, an advisory panel said after concluding that all three medicines posed some level of heart risk. The 17-15 vote on Vioxx's safety to go to market electrified Merck shares, which closed up 13 percent at $32.61 on the New York Stock Exchange. Pfizer Inc. (NYSEFE - News) gained 6.9 percent to close at $26.80. .